Long-term survival results of a randomized trial comparing gemcitabine/ cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Roberts, J Trevor ^b   von der Maase, H ^a   Sengelov L ^b   Conte, P F ^c   Dogliotti, L ^d   Oliver, T ^e   Moore, M J ^f   Zimmermann, A ^g   Arning, M ^g  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c SANTA CHIARA HOSPITAL   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Bladder cancer; Cisplatin; Gemcitabine; Survival

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; ADVANCED CANCER; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DEATH; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

EID: 33745597921     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj965     Document Type: Article

References (14)

1. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-407.
2. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
3. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelial. Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
4. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997; 15: 2564-2569.
5. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003; 3: 11-19.
6. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results at a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
7. Robinson P, von der Maase H, Bhalla S et al. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Rev of Pharmacoeconomics Outcomes Res 2004; 4: 27-38.
8. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-115.
9. von der Maase H, Andersen L, Crino L et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial. Ann Oncol 1999; 10: 1461-1465.
10. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 2876-2881.
11. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18: 1921-7.
12. Stadler WM, Hayden A, von der Maase H et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urologic Oncology 2002; 7: 153-7.
13. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-81.
14. Sengeløv L, Kamby C, von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 2001; 39: 634-642.